- Home
- GROY vs CRVS Comparison
GROY vs CRVS Comparison
Compare GROY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- CRVS
- Stock Information
- Founded
- GROY 2020
- CRVS 2014
- Country
- GROY Canada
- CRVS United States
- Employees
- GROY 16
- CRVS N/A
- Industry
- GROY
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GROY
- CRVS Health Care
- Exchange
- GROY Nasdaq
- CRVS Nasdaq
- Market Cap
- GROY 618.0M
- CRVS 305.4M
- IPO Year
- GROY 2021
- CRVS 2016
- Fundamental
- Price
- GROY $3.62
- CRVS $5.75
- Analyst Decision
- GROY Strong Buy
- CRVS Strong Buy
- Analyst Count
- GROY 4
- CRVS 4
- Target Price
- GROY $4.58
- CRVS $15.00
- AVG Volume (30 Days)
- GROY 2.5M
- CRVS 518.7K
- Earning Date
- GROY 08-06-2025
- CRVS 08-07-2025
- Dividend Yield
- GROY N/A
- CRVS N/A
- EPS Growth
- GROY N/A
- CRVS N/A
- EPS
- GROY N/A
- CRVS N/A
- Revenue
- GROY $12,376,000.00
- CRVS N/A
- Revenue This Year
- GROY $82.74
- CRVS N/A
- Revenue Next Year
- GROY $51.73
- CRVS N/A
- P/E Ratio
- GROY N/A
- CRVS N/A
- Revenue Growth
- GROY 90.37
- CRVS N/A
- 52 Week Low
- GROY $1.16
- CRVS $2.54
- 52 Week High
- GROY $3.65
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GROY 65.91
- CRVS 65.10
- Support Level
- GROY $2.89
- CRVS $5.28
- Resistance Level
- GROY $3.37
- CRVS $5.64
- Average True Range (ATR)
- GROY 0.15
- CRVS 0.30
- MACD
- GROY 0.01
- CRVS 0.03
- Stochastic Oscillator
- GROY 85.59
- CRVS 77.70
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).